



**MedDRA**  
Medical Dictionary  
for Regulatory Activities

## Coding with MedDRA



1



**MedDRA**

MedDRA was developed under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The activities of the MedDRA Maintenance and Support Services Organization (MSSO) are overseen by an ICH MedDRA Management Committee, which is composed of the ICH parties, the Medicines and Healthcare products Regulatory Agency (MHRA) of the UK, Health Canada, and the WHO (as Observer).

000894



2



## Disclaimer & Copyright Notice

- This presentation is protected by copyright and may, with the exception of the MedDRA and ICH logos, be used, reproduced, incorporated into other works, adapted, modified, translated or distributed under a public license provided that ICH's copyright in the presentation is acknowledged at all times. In case of any adaption, modification or translation of the presentation, reasonable steps must be taken to clearly label, demarcate or otherwise identify that changes were made to or based on the original presentation. Any impression that the adaption, modification or translation of the original presentation is endorsed or sponsored by the ICH must be avoided.
- The presentation is provided "as is" without warranty of any kind. In no event shall the ICH or the authors of the original presentation be liable for any claim, damages or other liability arising from the use of the presentation.
- The above-mentioned permissions do not apply to content supplied by third parties. Therefore, for documents where the copyright vests in a third party, permission for reproduction must be obtained from this copyright holder.

000854

3



## Course Overview

- Describe MedDRA's background, scope, structure, and characteristics (including primary SOC allocation rules)
- Discuss the maintenance of MedDRA, coding conventions, synonym lists, and coding quality assurance
- Introduce the MedDRA Term Selection: Points to Consider document
- Discuss and present examples of coding exercises with MedDRA

000894

4

4



## MedDRA Background

000894

5

5



## What is MedDRA?

**M**ed = Medical  
**D** = Dictionary for  
**R** = Regulatory  
**A** = Activities

000894

6

6



## MedDRA Definition

MedDRA is a clinically-validated international medical terminology used by regulatory authorities and the regulated biopharmaceutical industry. The terminology is used through the entire regulatory process, from pre-marketing to post-marketing, and for data entry, retrieval, evaluation, and presentation.

000894

7

7



## MedDRA's Purpose

- Facilitate the exchange of clinical information through standardization
- Important tool for product evaluation, monitoring, communication, electronic records exchange, and oversight
- Supports coding (data entry) and retrieval and analysis of clinical information about human medical products including pharmaceuticals, biologics, vaccines, and drug-device combination products

000894

8

8



## MedDRA and the MSSO



**MSSO**  
International support and development of terminology  
"Custodians", not owners, of the terminology



**Governance**  
Governed by a Management Committee (industry, regulators, multi-national, other interested parties)



**Educational offerings**  
Foster use of MedDRA through communications and educational offerings



**JMO**  
Partner organization for Japanese-language MedDRA



000894

9

9



## Where MedDRA is Used



Preclinical Testing



Clinical Phase I → Clinical Phase II → Clinical Phase III → APPROVAL → Marketed Product Phase IV




Regulatory Authority and Industry Databases  
Individual Case Safety Reports and Safety Summaries  
Clinical Study Reports  
Investigators' Brochures  
Core Company Safety Information  
Marketing Applications  
Publications  
Prescribing Information  
Advertising

000894



10

10



MedDRA Global View

MedDRA is in over 130 countries

000894 11

A world map showing the global reach of MedDRA, with most countries colored blue and a few highlighted in grey. The MedDRA logo is in the top left corner. The text "MedDRA Global View" is at the top right. Below the map, the text "MedDRA is in over 130 countries" is centered. The slide number "11" is in the bottom right corner.

11




MedDRA

MedDRA's Scope, Structure, and Characteristics


000894 12

The MedDRA logo is in the top left corner. The text "MedDRA's Scope, Structure, and Characteristics" is centered in green. The slide number "12" is in the bottom right corner.


12



13



14




**System Organ Classes**

000894 15

- Blood and lymphatic system disorders
- Cardiac disorders
- Congenital, familial and genetic disorders
- Ear and labyrinth disorders
- Endocrine disorders
- Eye disorders
- Gastrointestinal disorders
- General disorders and administration site conditions
- Hepatobiliary disorders
- Immune system disorders
- Infections and infestations
- Injury, poisoning and procedural complications
- Investigations
- Metabolism and nutrition disorders
- Musculoskeletal and connective tissue disorders
- Neoplasms benign, malignant and unspecified (incl cysts and polyps)
- Nervous system disorders
- Pregnancy, puerperium and perinatal conditions
- Product issues
- Psychiatric disorders
- Renal and urinary disorders
- Reproductive system and breast disorders
- Respiratory, thoracic and mediastinal disorders
- Skin and subcutaneous tissue disorders
- Social circumstances
- Surgical and medical procedures
- Vascular disorders

15



**The Five Levels of MedDRA**

000894 16

Level	MedDRA Code	Definition
SOC		Cardiac disorders
HLGT		Cardiac arrhythmias
HLT		Rate and rhythm disorders NEC
PT		Arrhythmia
LLT		LLT Arrhythmia NOS LLT Arrhythmia <b>LLT (Non-current) Other specified cardiac dysrhythmias</b> LLT Dysrhythmias

Note: Not all HLTs, HLTs, PTs or LLTs shown

16


 **MedDRA** | **Non-Current Terms** LLT

- Flagged at the LLT level in MedDRA
- Not recommended for continued use
- Retained to preserve historical data for retrieval and analysis
- Terms that are vague, ambiguous, outdated, truncated, or misspelled
- Terms derived from other terminologies that do not fit MedDRA rules

000894  17

17

 **MedDRA** | **MedDRA Codes**

**PT Anaemia**  
[10002034]  18

- Each MedDRA term is assigned an 8-digit numeric code
  - Non-expressive
  - Assigned sequentially
- Codes can fulfill a data field in various electronic submission types (e.g., E2B)

000894

18

# Current and Planned MedDRA Translations

10013211

000894

19




# MedDRA


## A Multi-Axial Terminology

Multi-axial = the representation of a medical concept in multiple SOCs

20



21



22



## Primary SOC Priority

If a PT links to more than one of the exceptions, the following priority will be used to determine primary SOC:

- 🥇 *Congenital, familial and genetic disorders*
- 🥈 *Neoplasms benign, malignant and unspecified (incl cysts and polyps)*
- 🥉 *Infections and infestations*

000894

23



## A Multi-Axial Terminology (cont)

PTs in the following SOCs **only** appear in that particular SOC and not in others, i.e., they are not multi-axial

- *Investigations*
- *Surgical and medical procedures*
- *Social circumstances*

000894

24

 **MedDRA**

## Can You Select the Primary SOC for This PT?

PT	HLT	HLGT	SOC
Congenital HIV infection	Viral infections congenital	Infections and infestations congenital	Congenital, familial and genetic disorders
	Congenital neonatal infections	Neonatal and perinatal conditions	Pregnancy, puerperium and perinatal conditions
	Retroviral infections	Viral infectious disorders	Infections and infestations
	Acquired immunodeficiency syndromes	Immunodeficiency syndromes	Immune system disorders

000894 25

25

 **MedDRA**

## MedDRA Maintenance

000894 26

26



MedDRA

## MedDRA Maintenance

- Users can send change requests (CRs) to MSSO for consideration
  - Organizations allowed 100 CRs/month
  - Rigorous medical review by MSSO physicians
  - For simple changes (PT and LLT levels), response within 7-10 working days
  - Complex changes (above PT level) posted for comments mid-year
- Two MedDRA updates/year
  - 1 March X.0 (Complex release)
  - 1 September X.1 (Simple release)

000894

27

27



MedDRA

## WebCR

- Web-based tool for Change Requests (CR)
  - URL: <https://mssotools.com/webcr/>
  - Via the Change Request Information page
- Ability to submit CRs online
  - Requests must be in English
- Immediate confirmation
- Review unsubmitted CRs online
- Ability to query CR history back to v5.1

000894

28

28



## Submitting Changes




- Online change request submission tool guides user to enter all needed information
- Instructional video on use of WebCR on “Training” page of MedDRA website

000894

29



## Submitting Changes (cont)



- Sample entry for a new PT in WebCR
- Justification and supporting documentation is important to help MSSO understand the need

000894

30



## Proactive MedDRA Maintenance

- What is the proactive approach?
  - Corrections/improvements made internally by the MSSO
  - General changes suggested by users
- Submitting ideas
  - Send to MSSO Help Desk. Justification is helpful.
  - Example: Review placement of bruise and contusion terms to facilitate coding and analysis
- Evaluation of proposals
  - Final disposition is not time limited; MSSO may take time to review
  - Proactive approach does not replace usual CR process

000894

31



## MedDRA Version Analysis Tool (MVAT)

- Web-based (<https://tools.meddra.org/mvat>)
- Free to all users
- Features
  - Version Report Generator (produces exportable report comparing any two versions)
  - Data Impact Report (identifies changes to a specific set of MedDRA terms or codes uploaded to MVAT)
  - Search Term Change (identifies changes to a single MedDRA term or code)

000894

32

32

 **MedDRA**

## MedDRA Version Analysis Tool (MVAT) (cont)

- User interface and report output available in all MedDRA languages
- Ability to run reports on supplemental changes
- Option to run reports on secondary SOC changes



000894

33

 **MedDRA**

## MedDRA Version Analysis Tool

 **MVAT**  
MedDRA Version Analysis Tool

IMO/95001  
Saturday, March 11, 2023 3:47 PM  
MedDRA End User License Agreement  
MedDRA Privacy Statement

**MedDRA Version Analysis Tool (MVAT)**

Version Report Description

Select Different Versions to Compare

Language: English

Starting Version: MedDRA 25.1 English

Ending Version: MedDRA 26.0 English

Include Secondary SOC Information

Select SOCs to filter (default is all SOCs)

- Blood and lymphatic system disorders
- Cardiac disorders
- Congenital, familial and genetic disorders
- Ear and labyrinth disorders
- Endocrine disorders
- Eye disorders
- Gastrointestinal disorders
- General disorders and administration site conditions
- Hepatobiliary disorders
- Immune system disorders
- Infections and infestations
- Injury, poisonings and procedural complications

Preferred Language: English


Release: English/Supplemental

MVAT Home  
Search Term Change  
Data Impact Report  
Logout



000894

34



**MedDRA** | **MSSO's MedDRA Browsers**


**MedDRA Desktop Browser (MDB)**  
Download MDB and release files from MedDRA website

**MedDRA Web-Based Browser (WBB)**  
<https://tools.meddra.org/wbb/>

**Mobile MedDRA Browser**  
<https://mmbr.meddra.org>

00084 35

35



**MedDRA** | **MSSO's MedDRA Browsers (cont)**

- **Features**
  - Each require MedDRA ID and password
  - View/search MedDRA and SMQs
  - Support for all MedDRA languages
  - Language specific interface
  - Ability to export search results and Research Bin to local file system (MDB and WBB only)

000894 36

36

 **MedDRA**

## MDB and WBB Special Features

- Preview upcoming (supplemental) changes in next release\*
 

*\*Supplemental view not available on MDB*
- View primary **and** secondary link information
- Upload terms to run against SMQs
- Advanced search options (e.g., NOT, OR)

000894

37




37


 **MedDRA**

## Data WBB Supplemental View

- Where will Change Requests I submitted appear in next release of MedDRA?
- What are the changes in an area of MedDRA in the next release?

000894

38





38




## WBB Supplemental View (cont)

- Display changes color to pink
- Supplemental terms highlighted by broken green line
- Changes for the next release are displayed immediately after they are approved by the MSSO



000894
39




## MedDRA Browser Demonstration and Instruction

000894

40
40



MedDRA

## Coding Exercises



000894

41


41



MedDRA

## Assessing the Reported Information

- Consider what is being reported. Is it a:
  - Clinical condition - Diagnosis, sign or symptom?
  - Indication?
  - Test result?
  - Injury?
  - Procedure?
  - Medication error?
  - Product use issue?
  - Product quality issue?
  - Social circumstance?
  - Device issue?
  - Procedural complication?
  - **Is it a combination of these?**



The type of report will influence the way you search for a suitable LLT. It may indicate in which SOC you expect to find the closest match.



000894

42

42



MedDRA

## MedDRA Browsing Tips



- First, try using reporter's actual words
- Be aware of MedDRA's specificity
- Exploit MedDRA's hierarchy – if an LLT is close to what you need, look at its "siblings" and "parent"
- Check where the LLT lies in MedDRA (i.e., check the hierarchy above to be sure it represents the verbatim term accurately)

000894



43

43




MedDRA

## MedDRA Browsing Tips (cont)




- Use "top-down" and "bottom-up" navigation
- Use available resources for difficult verbatim terms (web search, medical dictionaries, colleagues)
- Use advanced Boolean search terms features (i.e., "begins with", "exact match", "ends with", "not contains", "and", "or") when needed
- Become familiar with MedDRA Concept Descriptions

000894



44

44




MedDRA Concept Descriptions

- Descriptions of how a concept is interpreted, used, and classified in MedDRA
- Not a definition
- Intended to aid accurate and consistent use of MedDRA
- Overcome differences in medical practice worldwide
- Accessible in MSSO's browsers

000894 45

45



MedDRA Concept Descriptions (cont)

MedDRA Browser

Preferred Language: English MedDRA Concept Descriptions Legends About Search History New Browser Window MedDRA Documentation User Guide

Language and Version Options: English English English 19.1

Browser View: SOC Display Options

Term: mssotools.com

MedDRA CONCEPT DESCRIPTIONS

This appendix provides a list of MedDRA concept descriptions. A concept description is a description of how a concept is interpreted, used, and classified within the MedDRA terminology and is not a definition. The concept descriptions are intended to aid the consistent and accurate use of MedDRA in coding, retrieval, and analysis and to overcome the differences of medicine practice worldwide. The MSSO expects this appendix to be a working document and grow as subscribers request additional concepts to be documented.

A B C D E F G H I J K L M N Q P Q R S T U V W X Y Z

**A**

**Abuse**

For the purposes of term selection and analysis of MedDRA-coded data, abuse is the intentional, non-therapeutic use by a patient or consumer of a product – over-the-counter or prescription – for a perceived reward or desired non-therapeutic effect including, but not limited to, “getting high” (euphoria). Abuse may occur with a single use, sporadic use or persistent use of the product.

000894 46

46



MedDRA

## Exercise 1

The patient states she has been experiencing headaches, dizziness and vertigo.

\_\_\_\_\_ LLT → \_\_\_\_\_ PT  
\_\_\_\_\_ LLT → \_\_\_\_\_ PT  
\_\_\_\_\_ LLT → \_\_\_\_\_ PT

000894



47



MedDRA

## Exercise 2

Lab results indicate an increase in erythrocytes.

\_\_\_\_\_ LLT → \_\_\_\_\_ PT

000894



48



MedDRA

## Exercise 3

Drug was contaminated with Staphylococcus.

\_\_\_\_\_ LLT → \_\_\_\_\_ PT

000894



49



MedDRA

## Exercise 4

A six year old boy was admitted for toxicity after accidentally ingesting the remaining antihypertensive tablets in the bottle.

\_\_\_\_\_ LLT → \_\_\_\_\_ PT  
\_\_\_\_\_ LLT → \_\_\_\_\_ PT

000894



50



MedDRA

## Exercise 5

The patient's urinary catheter was blocked.

\_\_\_\_\_ LLT → \_\_\_\_\_ PT

000894

51

51



MedDRA

## Coding with MedDRA

000894

52

52



## What are Coding Conventions?

- Written guides and sets of principles for using MedDRA that help achieve consistency in coding and data retrieval
- Conventions harmonize exchange of MedDRA coded data worldwide
- Common topics
  - Misspellings, abbreviations and acronyms
  - Combination terms and “due to” concepts
  - “Always query” terms, e.g., “Chest pain”

000894



53

53



## Why Do We Need Coding Conventions?

- Differences in medical aptitude of coders
- Consistency concerns (many more “choices” in MedDRA vs. older terminologies)
- Even with autoencoder, may still need manual coding



000894



54

54




MedDRA

## Autoencoder Pitfalls

- Inappropriate terms may be selected by autoencoder
- Review all autoencoding carefully
  - “Allergic to CAT scan” autoencoded as:  
LLT *Allergic to cats*
  - “Myocardial infarction in the fall of 2000” autoencoded as:  
LLT *Myocardial infarction*  
LLT *Fall*

000894



55

55



MedDRA

## Can I Make Coding Conventions Specific to My Company/Product?

- MedDRA may reduce the need to do this because:
  - Increased size/granularity results in more accurate representation of data
  - Secondary SOC allocations allow for different “views” of the data
- This type of approach should be done cautiously

000894



56

56



MedDRA

## Synonym Lists

- Recurring verbatims – one-time assignment to an LLT
- Promotes consistency
- Increases likelihood of autoencoding “hit”
- Maintenance required

Verbatim	LLT	Comment
Throbbing above temple Aching all over head Pulsing pain in head	Headache	
Muscular pain in legs	Myalgia of lower extremities	LLT <i>Myalgia of lower extremities</i> is a better choice than LLT <i>Muscular pain</i> since it captures both the event and body site

000894

57



MedDRA

## Quality Assurance (QA) Reports

- Allows reviewers to check for consistency (both auto-encoded and human-coded terms)
- Check for adherence to/deviation from coding conventions
- Check for emerging drifts/biases
- Multiple data views (verbatims to coded terms; coded term to verbatims; by SOC, etc.)

000894

58

58

 **MedDRA**

**QA Sample Report**

SOC	HLT	PT	Verbatim	Count	
Respiratory, thoracic and mediastinal disorders					
Bronchospasm and obstruction					
Wheezing					
WHEEZING					16
Wheeze					5
INCREASED WHEEZING					1
Breathing suppressed wheezing					1
HYPERREACTIVITY AND WHEEZING					1
wheeze in chest					1
Laryngeal and adjacent sites disorders NEC (excl infections and neopla					
Vocal cord disorder					
SPASMODIC DYSTONIA OF THE VOCAL CORDS					1
Newborn respiratory disorders NEC					
Transient tachypnoea of the newborn					
Transient hazy vision					1
Transient tachypnea, neonatal					1
Tachypnea of the newborn, transient					1

000894

59

 **Unqualified Test Name Term List**

- MSSO developed and maintains list of unqualified test name terms
  - These terms (e.g., PT *Blood glucose*) should never be reported as AEs
  - Intended for use in E2B test name field only
- List can be used to check data quality
  - Identifies inappropriate terms in data fields other than test name data element
  - Intended as recommendation only

000894

60



## Unqualified Test Name Term List (cont)

- Link on Support Documentation page on MedDRA website
- Spreadsheet of LLT/PT names and codes from SOC *Investigations*
  - >4,400 terms in v26.0
- Explanatory document
  - Purpose, uses, development of list
- Also available in Japanese on JMO website

000894

61

61



## MedDRA Term Selection: Points to Consider Document

000894

62

62

 **MedDRA**

## MedDRA Term Selection: Points to Consider (MTS:PTC)

**MedDRA® TERM SELECTION:  
POINTS TO CONSIDER**  
ICH-Endorsed Guide for MedDRA Users  
Release 4.23

March 2023

**Disclaimer and Copyright Notice**  
This document is protected by copyright and may, with the exception of the MedDRA and ICH logos, be used, reproduced, incorporated into other works, adapted, modified, translated or distributed under a public license provided that ICH's copyright in the document is not removed or altered. In the event of such adaptation, modification or translation of the document, reasonable steps must be taken to clearly label, demarcate or otherwise identify that changes were made to or based on the original document. Any impression that the adaptation, modification or translation of the original document is endorsed or sponsored by the ICH or its members is incorrect.

The document is provided "as is" without warranty of any kind. In no event shall the ICH or the authors of the original document be liable for any claim, damages or other liability arising from the use of the document.


The above-mentioned permissions do not apply to content supplied by third parties. Therefore, for documents where the copyright vests in a third party, permission for reproduction must be obtained from this copyright holder.

MedDRA® trademark is registered by ICH

000894

63

- Provides term selection advice for industry and regulatory purposes
- Objective is to promote accurate and consistent term selection to facilitate common understanding of shared data
- Recommended to be used as basis for individual organization's own coding conventions



 **MedDRA**

## MedDRA Term Selection: PTC (cont)

- Developed by a working group of the ICH Management Committee
- Updated annually in March
- Complete versions available in
  - English, Japanese, Chinese, Korean, Spanish, and Russian
- Condensed versions available for other MedDRA languages\*
- Available on MedDRA and JMO websites

\*Arabic, Brazilian Portuguese, Czech, Dutch, French, German, Hungarian, Italian, Portuguese

000894

64




**MTS:PTC Points of Note**

- In some cases, with more than one option for selecting terms, a “preferred option” is identified but this does not limit MedDRA users to applying that option. Organizations should be consistent in their choice of option.
- Section 4.1 – Versioning (Appendix)
  - 4.1.1 Versioning methodologies
  - 4.1.2 Timing of version implementation

000894 65

65


**PtC Documents**

PtC Category	PtC Document	Purpose	Languages	Release Cycle
Term Selection	MedDRA Term Selection: Points to Consider	Promote accurate and consistent coding with MedDRA	English, Japanese, Chinese, Russian, Korean, and Spanish	Updated annually with the March release of MedDRA
	MedDRA Term Selection: Points to Consider Condensed Version	Shorter version focusing on general coding principles to promote accurate and consistent use of MedDRA worldwide	All MedDRA languages (except English, Japanese, other languages with an available translation of the full MTS:PTC document, and EEA languages*)	Update as needed
Data Retrieval and Presentation	MedDRA Data Retrieval and Presentation: Points to Consider	Demonstrate how data retrieval options impact the accuracy and consistency of data output	English, Japanese, Chinese, Russian, Korean, and Spanish	Updated annually with the March release of MedDRA
	MedDRA Data Retrieval and Presentation: Points to Consider Condensed Version	Shorter version focusing on general retrieval and analysis principles to promote accurate and consistent use of MedDRA worldwide	All MedDRA languages (except English, Japanese, other languages with an available translation of the full DRP:PTC document, and EEA languages*)	Update as needed

\*The following European Economic Area (EEA) languages in MedDRA do not have translations of user documentation, including PtC documents: Bulgarian, Croatian, Danish, Estonian, Finnish, Greek, Icelandic, Irish, Latvian, Lithuanian, Maltese, Norwegian, Polish, Romanian, Slovak, Slovenian, Swedish

000894 66

66

 **MedDRA** | **PtC Documents (cont)**

PtC Category	PtC Document	Purpose	Languages	Release Cycle
General	MedDRA Points to Consider Companion Document	More detailed information, examples, and guidance on specific topics of regulatory importance. Intended as a "living" document with updates based on users' needs. First edition covered data quality and medication errors. Updated in July 2020 (Release 1.1). Release 2.0 in October 2020 included a section on product quality issues.	English and Japanese	Updated as needed




000894 67

67

 **MedDRA** | **General Term Selection Principles**

- Quality of Source Data
- Quality Assurance
- Do Not Alter MedDRA
- Always Select a Lowest Level Term
- Select Only Current Lowest Level Terms
- When to Request a Term
- Use of Medical Judgment in Term Selection
- Select Terms for All Reported Information, Do Not Add Information



000894 68

68



## Quality of Source Data Quality Assurance

- Quality of original information impacts quality of output
- Obtain clarification of data
- Can be optimized by careful design of data collection forms and proper training of staff
- Organizations' coding guidelines should be consistent with MTS:PTC
- Review of term selection by qualified individuals
- Human oversight of automated coding results

000894

69

69



## Do Not Alter MedDRA

- MedDRA is a standardized terminology with a pre-defined term hierarchy
- Users must not make *ad hoc* structural alterations, including changing the primary SOC allocation



If terms are incorrectly placed, submit a change request to the MSSO

000894

70

70

 **MTS:PTC General Principle**


- **Always Select a Lowest Level Term**  
**Select Only Current LLTs**

✓ Select the Lowest Level Term that most accurately reflects the reported verbatim information

**“Abscess on face”**

→ Do not simply select LLT *Abscess*

→ Select a term with greater specificity **LLT *Facial abscess***



✓ Select current LLTs only  
– Non-current terms for legacy conversion/historical purposes

000894

71

 **When to Request a Term**  
**Use of Medical Judgment**

- Avoid company-specific “work-arounds” for MedDRA deficiencies. If concept not adequately represented in MedDRA, submit Change Request to MSSO.
- If no exact match in MedDRA, use medical judgment to match to an existing term that adequately represents the concept

000894

72



## Select Terms for All Reported Information

- Select terms for every AR/AE reported, regardless of causal association
- Select terms for device-related events, product quality issues, medication errors, medical and social history, investigations and indications as appropriate

000894

73

73



## Do Not Add Information

- Do not make diagnosis if only signs/symptoms reported

Reported	LLT Selected	Comment
Abdominal pain, increased serum amylase, and increased serum lipase	Abdominal pain	It is inappropriate to assign an LLT for diagnosis of "pancreatitis"
	Serum amylase increased	
	Lipase increased	

000894

74

74

 **General Principles**

 • Selecting More Than One Term

✓ Can select more than one LLT to represent reported information.
 

- Selecting one term may lead to loss of specificity
- Selecting more than one term may lead to redundant counts

**⚠ Document your procedures!**

Report:  
"Metastatic  
gingival cancer"

Select LLT Gingival cancer **OR** LLT  
Metastatic carcinoma

Select LLT Gingival cancer **AND** LLT  
Metastatic carcinoma

000894 75

75

 **Term Selection Points**

**Section 3**

- Diagnoses and Provisional Diagnoses with or without Signs and Symptoms
- Death and Other Patient Outcomes
- Suicide and Self-Harm
- Conflicting/Ambiguous/Vague Information
- Combination Terms
- Age vs. Event Specificity
- Body Site vs. Event Specificity
- Location-Specific vs. Microorganism-Specific Infection
- Modification of Pre-existing Conditions
- Exposures During Pregnancy and Breast Feeding
- Congenital Terms
- Neoplasms
- Medical and Surgical Procedures
- Investigations

000894 76

76

 **MedDRA** | **Term Selection Points**

Section 3

- Medication Errors, Accidental Exposures and Occupational Exposures
- Misuse, Abuse and Addiction
- Transmission of Infectious Agent via Product
- Overdose, Toxicity and Poisoning
- Device-related Terms
- Drug Interactions
- No Adverse Effect and "Normal" Terms
- Unexpected Therapeutic Effect
- Modification of Effect
- Social Circumstances
- Medical and Social History
- Indication for Product Use
- Off Label Use
- Product Quality Issues

000894

77

77

 **MedDRA** | **Important Coding Errors**

- **Missed Concepts**
  - All medical concepts described after the product is taken should be coded
  - Example: "*The patient took drug X and developed alopecia, increased LFTs and pancreatitis*". Manufacturer only codes alopecia and increased LFTs (missed concept of pancreatitis)
  - Example: "*The patient took drug X and developed interstitial nephritis which later deteriorated into renal failure*". Manufacturer only codes interstitial nephritis (missed renal failure concept)

000894

78

78



## Important Coding Errors (cont)

- “Soft Coding”
  - Selecting a term which is both less specific and less severe than another MedDRA term is “soft coding”
  - Example: “*Liver failure*” coded as hepatotoxicity or increased LFTs
  - Example: “*Aplastic anemia*” coded as unspecified anemia
  - Example: “*Rash subsequently diagnosed as Stevens Johnson syndrome*” coded as rash

000894

79

79



## Diagnoses and Provisional Diagnoses

SINGLE DIAGNOSIS	
DEFINITIVE DIAGNOSIS	PROVISIONAL DIAGNOSIS
Single diagnosis without signs and symptoms <ul style="list-style-type: none"> <li>• Diagnosis (only possible option)</li> </ul>	Single provisional diagnosis without signs and symptoms <ul style="list-style-type: none"> <li>• Provisional diagnosis (only possible option)</li> </ul>
Example: “ <i>Myocardial infarction</i> ” → select “ <i>Myocardial infarction</i> ”	Example: “ <i>Possible myocardial infarction</i> ” → select “ <i>Myocardial infarction</i> ” (select term as if definitive diagnosis)

000894



Similar principles apply for multiple diagnoses

80

80



## Diagnoses and Provisional Diagnoses (cont)

SINGLE DIAGNOSIS	
DEFINITIVE DIAGNOSIS	PROVISIONAL DIAGNOSIS
Single diagnosis with signs/symptoms  •Preferred: Diagnosis only	Single provisional diagnosis with signs/symptoms  •Preferred: Provisional diagnosis and signs/symptoms
Example: "Anaphylactic reaction with rash, dyspnoea, hypotension, and laryngospasm" → select "Anaphylactic reaction"	Example: "Possible myocardial infarction with chest pain, dyspnoea, diaphoresis" → select "Myocardial infarction", "Chest pain", "Dyspnoea", and "Diaphoresis"

000894



Similar principles apply for multiple diagnoses

81

81



## Diagnoses and Provisional Diagnoses (cont)

SINGLE DIAGNOSIS	
DEFINITIVE DIAGNOSIS	PROVISIONAL DIAGNOSIS
Single diagnosis with signs/symptoms  •Alternate: Diagnosis and signs/symptoms	Single provisional diagnosis with signs/symptoms  •Alternate: Signs/symptoms only (as provisional diagnosis may change)
Example: "Anaphylactic reaction with rash, dyspnoea, hypotension, and laryngospasm" → select "Anaphylactic reaction", "Rash", "Dyspnoea", "Hypotension", and "Laryngospasm"	Example: "Possible myocardial infarction with chest pain, dyspnoea, diaphoresis" → select "Chest pain", "Dyspnoea", and "Diaphoresis"

000894



Similar principles apply for multiple diagnoses

82

82



## Diagnoses and Provisional Diagnoses (cont)

- Always include signs/symptoms not associated with diagnosis

Reported	LLT Selected
Myocardial infarction, chest pain, dyspnoea, diaphoresis, ECG changes and jaundice	Myocardial infarction Jaundice (note that jaundice is not typically associated with myocardial infarction)

000894

83

83



## What Terms to Select?

- Sepsis leading to shock from possible spontaneous bacterial peritonitis or bowel perforation

Sepsis  
 Shock  
 Septic shock  
 Spontaneous bacterial peritonitis  
 Bowel perforation

000894

84

84



## Conflicting/Ambiguous Information

- First, try to obtain more specific information

Reported	LLT Selected	Comment
Hyperkalaemia with a serum potassium of 1.6 mEq/L	Serum potassium abnormal	LLT <i>Serum potassium abnormal</i> covers both of the reported concepts (note: serum potassium of 1.6 mEq/L is a low result, not high)
GU pain	Pain	“GU” could be either “genito-urinary” or “gastric ulcer”. If additional information is not available, then select a term to reflect the information that is known, i.e., LLT <i>Pain</i>

000894

85

85



## Vague Information

- First, try to obtain more specific information

Reported	LLT Selected	Comment
Turned green	Unevaluable event	“Turned green” reported alone is vague; this could refer to a patient condition or even to a product (e.g., pills)
Patient had a medical problem of unclear type	III-defined disorder	Since it is known that there is some form of a medical disorder, LLT <i>III-defined disorder</i> can be selected

000894

86

86



MedDRA

## What Terms to Select?

- Clinical complication of IUD
  - IUD complication (PT Complication associated with device)
  - Intra-uterine death (PT Foetal death)
  - Unevaluable event
- Hypoglycemia (blood glucose = 200 mg/dL)
  - Blood glucose abnormal
  - Blood glucose increased
  - Hypoglycemia

000894

87

87



MedDRA

## Combination Terms

- One condition is more specific than the other

Reported	LLT Selected
Arrhythmia due to atrial fibrillation	Atrial fibrillation
Hepatic function disorder (acute hepatitis)	Hepatitis acute

- A MedDRA combination term is available

Reported	LLT Selected
Retinopathy due to diabetes	Diabetic retinopathy
Rash with itching	Itchy rash
Breast cancer (HER2 positive)	HER2 positive breast cancer

000894

88

88



MedDRA

## Combination Terms (cont)

- If splitting provides more clinical information, select more than one term
- In all cases of combination terms, apply medical judgment

Reported	LLT Selected
Diarrhoea and vomiting	Diarrhoea Vomiting
Wrist fracture due to fall	Wrist fracture Fall
BRAF positive malignant melanoma	BRAF gene mutation Malignant melanoma

000894

89



MedDRA

## What Terms to Select?

- Retinal disease from HIV with near total blindness (R and L)

Retinal damage  
 Retinal disorder  
 HIV disease  
 Blindness  
 HIV retinopathy  
 Blindness, both eyes

000894

90



MedDRA

## Investigations

- Medical condition vs. investigation result

Reported	LLT Selected	Comment
Hypoglycaemia	Hypoglycaemia	LLT <i>Hypoglycaemia</i> links to SOC <i>Metabolism and nutrition disorders</i>
Decreased glucose	Glucose decreased	LLT <i>Glucose decreased</i> links to SOC <i>Investigations</i>

000894

91

91



MedDRA

## Investigations (cont)

- Unambiguous investigation result

Reported	LLT Selected	Comment
Glucose 40 mg/dL	Glucose low	Glucose is clearly below the reference range

- Ambiguous investigation result

Reported	LLT Selected	Comment
His glucose was 40	Glucose abnormal	No units have been reported. Select LLT <i>Glucose abnormal</i> if clarification cannot be obtained.

000894

92

92



MedDRA

## Investigations (cont)

- Investigation results consistent with diagnosis

Reported	LLT Selected	Comment
Elevated potassium, K 7.0 mmol/L, and hyperkalaemia	Hyperkalaemia	It is not necessary to select LLT <i>Potassium increased</i>

- Grouped investigation result terms

Reported	LLT Selected	Comment
Increased alkaline phosphatase, increased SGPT, increased SGOT and elevated LDH	Alkaline phosphatase increased SGPT increased SGOT increased LDH increased	Select four individual terms. A single term such as LLT <i>Liver function tests abnormal</i> should not be selected.

000894

93

93



MedDRA

## What Terms to Select?

- Testing showed increased serum creatinine and BUN, with increased BUN/creatinine ratio

Increased serum creatinine  
 BUN increased  
 Blood urea nitrogen/creatinine ratio increased  
 Renal function tests NOS abnormal

- Patient had features of aldosterone excess

Aldosterone increased  
 Aldosteronism  
 Blood aldosterone abnormal

000894

94

94

 **MedDRA** | **Medication Errors**



- See MedDRA Concept Descriptions
- Discussed in MedDRA Points to Consider Companion Document – Section 3
  - Detailed examples
  - “Questions and Answers” about medication errors
- “Top-down” navigation in HLGT *Medication errors and other product use errors and issues* is best approach for term selection

000894  95

95

 **MedDRA** | **Medication Errors (cont)**

- Medication error with clinical consequences

Reported	LLT Selected	Comment
Patient was administered wrong drug and experienced hypotension	Wrong drug administered Hypotension	
Insulin was given using the wrong syringe resulting in the administration of an overdose. The patient developed hypoglycaemia.	Drug administered in wrong device Accidental overdose Hypoglycaemia	If an overdose is reported in the context of a medication error, the more specific term <i>LLT Accidental overdose</i> can be selected

000894  96

96



MedDRA

## Medication Errors (cont)

- Medication error without clinical consequences

Reported	LLT Selected	Preferred Option
Medication was given intravenously instead of intramuscularly without any adverse effect	Intramuscular formulation administered by other route	✓
	Intramuscular formulation administered by other route	
	No adverse effect	

000894

97

97



MedDRA

## Medication Errors (cont)

- Important to record potential occurrence of medication error
- Unlikely to be reported as an adverse event but may need to be recorded in periodic safety reports

Reported	LLT Selected	Comment
Pharmacist notices that the names of two drugs look similar and is concerned that this may result in a medication error	Drug name look-alike Circumstance or information capable of leading to medication error	Note: this example is a potential medication error. LLT <i>Drug name look-alike</i> provides additional information about the nature of the potential medication error, and LLT <i>Circumstance or information capable of leading to medication error</i> indicates that there is a potential medication error.

000894

98

98



## Overdose, Toxicity and Poisoning

If overdose, poisoning or toxicity is explicitly reported, select the appropriate term


- Overdose with clinical consequences

Reported	LLT Selected
Stomach upset from study drug Overdose	Stomach upset Overdose

- Overdose without clinical consequences

Reported	LLT Selected	Preferred Option
Patient received an overdose of medicine without any adverse consequences	Overdose	✓
	Overdose No adverse effect	

000894



99

99



## What Term(s) to Select?

- The patient's renal function was measured every six months instead of on the monthly schedule recommended in the label for the drug
  - Medication monitoring error
  - Renal function test abnormal
  - Drug monitoring procedure incorrectly performed
- Unintentionally took more than maximum recommended dose due to dispensing error
  - Accidental overdose
  - Incorrect dose administered
  - Drug dispensing error

000894



100

100



## Death and Other Patient Outcomes

- Death, disability and hospitalization are considered outcomes and not usually coded as adverse events (AE) or adverse reactions (AR)
- If one of these outcomes is the only reported information, select an appropriate LLT for coding
- If a death term in MedDRA adds important clinical information, code it along with reported ARs/AEs

Reported	LLT Selected
Patient experienced a rash and had sudden cardiac death	Rash Sudden cardiac death

000894

101

101



## Drug Interactions

- Term includes reactions between drugs (including biologic products) and other drugs, foods, devices and alcohol
- If reporter states an interaction, select terms for interaction term and reported medical event(s)

Reported	LLT Selected
Patient drank cranberry juice which interacted with anticoagulant drug causing an INR increase	Food interaction INR increased

000894

102

102



MedDRA

## Suicide and Self-Harm

- Coding of suicide attempts, completed suicides and self-harm should be accurate and consistent
- Do not assume that an overdose, even if intentional, is a suicide attempt
- If a self-harm report does not mention suicide or suicide attempt, only code self-injury term
- If a suicide attempt is fatal, select a term that reflects the outcome instead of the attempt

Reported	LLT Selected	Comment
Suicide attempt resulted in death	Completed suicide	Report death as an outcome

000894

103

103



MedDRA

## What Term to Select?

- Death from cerebral hemorrhage

Sudden death  
 Death  
 Cerebral hemorrhage  
 Brain death

000894

104

104



MedDRA

## What Term to Select?

- Patient was found dead

Death from natural causes

Death

Died in sleep

Found dead

000894

105

105



MedDRA

## What Term(s) to Select?

- After taking an antihistamine along with her prescription proton pump inhibitor, a 53-year-old woman developed vertigo

Drug interaction NOS

Vertigo subjective

Vertigo

Drug interaction

000894

106

106



MedDRA

## What Term(s) to Select?

- Deliberately took an overdose

Intentional overdose

Suicide attempt

Deliberate overdose

Overdose NOS

000894

107

107



MedDRA

## Misuse, Abuse and Addiction

Concept	Intentional?	By Whom?	Therapeutic Use?	Additional Sections in this Document
Misuse	Yes	Patient/consumer	Yes*	3.16.1
Abuse	Yes	Patient/consumer	No	3.16.2
Addiction	Yes	Patient/consumer	No	3.16.3
Medication error	No	Patient/consumer or healthcare provider	Yes	3.15
Off label use	Yes	Healthcare provider	Yes	3.27

\* Definitions of misuse may not always include the concept of therapeutic use; misuse may be similar to the concept of abuse in some regions.

000894

108

108



MedDRA

## Coding Exercises

- Narratives and short verbatims
- Assess the reported terms
  - Identify what concepts are reported (diagnosis, death, investigations, etc.)
- Refer to the appropriate sections of the MTS:PTC for guidance on term selection
  - For example, Section 3.2 for death terms
- Use MTS:PTC preferred options (forget your organization's conventions)
- Use browser to search for and select LLTs

000894

109

109



MedDRA

## Specific Tips for Narrative Exercises

- Overall, coding principles are the same as for short verbatim exercises
- Code all of the following:
  - Events (including procedures and investigations as needed)
  - Indications
  - Medical history
  - Social history

000894

110

110



## Sample Narrative

A 75-year-old male receiving Drug X for rheumatoid arthritis developed an area of darkened skin on his chest. The patient's medical history is significant for peripheral vascular disease and cigarette smoking. The skin lesion was excised; it was revealed to be a seborrheic wart.

000894

111

111



## Course Summary

- ✓ Described MedDRA's background, scope, and structure (including primary SOC allocation rules)
- ✓ Discussed maintenance of MedDRA, coding conventions, synonym lists, and coding QA
- ✓ Introduced the MedDRA Term Selection: Points to Consider document
- ✓ Discussed and presented examples of coding exercises with MedDRA

000894

112

112



**MSSO Contacts**

- Website
  - [www.meddra.org](http://www.meddra.org)
- Email
  - [mssohelp@meddra.org](mailto:mssohelp@meddra.org)
- Frequently Asked Questions
  - [www.meddra.org/faq](http://www.meddra.org/faq)
- MedDRA Browsers
  - <https://www.meddra.org/meddra-desktop-browsers>  
(Desktop Browser)
  - <https://tools.meddra.org/wbb/> (Web-Based Browser)
  - <https://mbb.meddra.org> (Mobile Browser)

000894 113

113




**MSSO Contacts (cont)**


- Change Request Submission
  - <https://www.meddra.org/how-to-use/change-requests>
- Training Schedule
  - <https://www.meddra.org/training/schedule>
- MedDRA Support Documentation
  - <https://www.meddra.org/how-to-use/support-documentation>

000894 114

114



115



116